Researchers have published initial results from a clinical trial using focused ultrasound neuromodulation for the treatment of opioid use disorder.
The intervention significantly reduced substance cravings, and most participants did not use opioids or other substances during the 90-day follow-up period.
Philip Bergman, DVM, MS, PhD, DACVIM-Oncology, will serve as a consultant to the veterinary and the cancer immunotherapy programs.
He was director of clinical studies for VCA Animal Hospitals and Mars Veterinary Hospital and is the principal veterinary investigator for the canine melanoma vaccine.
“The Foundation has been pivotal in helping to establish cross collaborations with major veterinary practice networks. I am deeply grateful for the Foundation’s invaluable contributions to this field.”